Testing effectiveness (Phase 2)Active Not RecruitingNCT06245915
What this trial is testing
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Who this might be right for
Advanced/Metastatic Clear Cell Renal Cell CarcinomaRecurrence
Arsenal Biosciences, Inc. 37